FindTrial
Sign In

Effect of nasal block given through nasal spray technique on post spinal anesthesia headache

Comparison between intranasal bupivacaine delivered through mucosal atomization device and sphenopalatine ganglion block in patients having Post Dural Puncture Headache - A non inferiority randomized clinical trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057566
Enrollment
42
Registered
2023-09-13
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G891- Acute pain, not elsewhere classified

Interventions

Intervention1: Group M (Intervention group): Group M (Intervention group) will be given intranasal 0.5% Bupivacaine using Mucosal Atomization Device, 1 ml in each nostril Control Intervention1: Group

Sponsors

AIIMS Bhubaneswar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA 1-3 post partum women diagnosed as post-dural puncture headache as per ICHD3 criteria

Exclusion criteria

Exclusion criteria: no consent, allergy to bupivacaine, active nasal discharge or bleeding, psychiatric disorder

Design outcomes

Primary

MeasureTime frame
VAS score at 1 hourTimepoint: 1 hour—

Secondary

MeasureTime frame
vas scoreTimepoint: baseline, 30 minutes, 12 hours, 24 hours;consumption of rescue tramadolTimepoint: 24 hours;patient discomfort score due to procedureTimepoint: 30 minutes;patient activity level scoreTimepoint: 24 hours;ease of administration of two methodsTimepoint: 30 mins;MCA peak and mean flow velocities in TCDTimepoint: baseline, 1 hour after intervention—

Countries

India

Contacts

Public ContactNitasha Mishra

AIIMS Bhubaneswar

anaes_nitasha@aiimsbhubaneswar.edu.in8373938016

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026